A Randomized Phase II Clinical Trial of High-Dose Nicotine Patch Therapy for Smokeless Tobacco Users

Ebbert, Jon O.; Croghan, Ivana T.; Schroeder, Darrell R.; Hurt, Richard D.
December 2013
Nicotine & Tobacco Research;Dec2013, Vol. 15 Issue 12, p2037
Academic Journal
Introduction: Nicotine patch therapy has not been shown to be efficacious for increasing long-term (≥6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Higher doses of nicotine patch therapy may be needed to increase tobacco abstinence rates in this population of tobacco users. Methods: We randomized ST users who used ≥3 cans/pouches per week to either 8 weeks of high-dose nicotine patch therapy (42mg/day) or matching placebo patch. Subjects were followed for 6 months after randomization. Results: Fifty-two subjects were randomized. Compared with placebo, high-dose nicotine patch therapy was associated with significantly higher prolonged tobacco abstinence at end-of-treatment (44% vs. 22%, odds ratio [OR] = 2.7, p = .050) and 3 months (40% vs. 19%, OR = 2.9, p = .047). High-dose nicotine patch therapy was associated with significant weight gain attenuation among tobacco abstinence subjects at 3 months (p = .013) and 6 months (p = .018). Compared with placebo, high-dose nicotine patch therapy was associated with nonsignificantly lower nicotine withdrawal scores. Adverse events were not significantly increased with high-dose nicotine patch therapy. Conclusions: High-dose nicotine patch therapy is safe and increases short-term tobacco abstinence rates among ST users who use ≥3 cans/pouches per week. High-dose nicotine patch therapy is associated with significant long-term attenuation of weight gain. Future studies to investigate the long-term efficacy of high-dose nicotine patch therapy and the comparative efficacy of this approach compared with standard nicotine patch doses for ST users seems warranted.


Related Articles

  • Effects of a Fact Sheet on beliefs about the harmfulness of alternative nicotine delivery systems compared with cigarettes. Borland, Ron; Lin Li; Cummings, K. Michael; O'Connor, Richard; Mortimer, Kevin; Wikmans, Tom; Ramstrom, Lars; King, Bill; McNeill, Ann // Harm Reduction Journal;2012, Vol. 9 Issue 1, p19 

    Background: This study explored the value of providing information in a Fact Sheet to correct misperceptions about the relative harmfulness of nicotine replacement products (NRT) and smokeless tobacco (ST), when compared to cigarette smoking. Methods: Four convenience samples from different...

  • Nicotine conjugate vaccines: A novel approach in smoking cessation. Kitchens, Caroline M.; Foster, Stephan L. // Journal of the American Pharmacists Association: JAPhA;Jan/Feb2012, Vol. 52 Issue 1, p116 

    The article discusses pharmacologic therapeutic options for smoking cessation in the U.S. These options are direct nicotine replacement therapy (NRT), anti-depressant medications and a nicotine receptor partial agonist. Dosage forms of NRT include chewing gums, lozenges, patches, nasal sprays...

  • Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. Schiller, Katherine R.; Luo, Xianghua; Anderson, Amanda J.; Jensen, Joni A.; Allen, Sharon S.; Hatsukami, Dorothy K. // Nicotine & Tobacco Research;Aug2012, Vol. 14 Issue 8, p902 

    Introduction: Relatively few studies have investigated pharmacological or behavioral treatment of smokeless tobacco (ST) users who do not have immediate quit plans. In this study, we compared a reduction treatment approach with an immediate cessation approach in a population of ST...

  • Oral nicotine solution for smoking cessation: a pilot tolerability study. Westman, Eric C.; Tomlin, Keith F.; Perkins, Christine E.; Rose, Jed E. // Nicotine & Tobacco Research;Nov2001, Vol. 3 Issue 4, p391 

    This study was conducted to determine the preliminary tolerability of an oral nicotine solution with minimal behavioral intervention for smoking cessation. Twenty-five healthy volunteers who smoked at least 10 cigarettes per day and were motivated to quit smoking were enrolled in an open-labeled...

  • Nicotine.  // Reactions Weekly;10/6/2012, Issue 1422, p36 

    The article describes the case of a 35-year-old man with bipolar disorder who experienced manic exacerbation after using nicotine patches to stop smoking cigarettes.

  • Do not overchew it. Godbey, Susan Flagg; George, Stephen // Prevention;Feb97, Vol. 49 Issue 2, p44 

    Reveals that prolonged use of nicotine replacements may affect insulin levels. Research by scientists at Sahlgrenska University Hospital in Goteborg, Sweden; Study of former tobacco users who had continued using nicotine gum with former tobacco users who had no nicotine; Recommended use for...

  • Should We Recommend Nicotine Replacement Therapy? David, Sean P. // American Family Physician;6/1/2001, Vol. 63 Issue 11, p2245 

    Evaluates the efficacy of nicotine replacement therapy for treating nicotine tolerance and dependence, in reference to a related review from the Cochrane Library. Criticisms on the Cochrane review; Abstract of the related review; Details on the administration of the therapy. INSET: Cochrane...

  • Information from Your Family Doctor. Using the Nicotine Patch, Nicotine Gum, Nicotine Nasal Spray or Nicotine Inhaler.  // American Family Physician;6/1/2001, Vol. 63 Issue 11, p2251 

    Presents information on the forms of nicotine replacement therapy. Nicotine patch; Nicotine gum; Nicotine nasal spray.

  • Effect of Nicotine Nasal Spray on Smoking Cessation.  // American Family Physician;4/1/1995, Vol. 51 Issue 5, p1253 

    Reports on an article by Hjalmarson and colleagues published in the November 28, 1994 issue of `Archives of Internal Medicine,' evaluating the efficacy and safety of nicotine nasal spray as an adjunct to group therapy in a smoking cessation clinic.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics